Tempus AI Wins FDA Clearance for ECG Pulmonary Hypertension Tool
Chicago, Illinois, USA, Aug 26, 2026 Tempus AI, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance...
Tempus AI
Advertisement
Tempus to Acquire Personalis in $1.5B Precision Oncology Deal
CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...
Tempus AI and Bristol Myers Squibb Expand AI Clinical Trial Partnership
CHICAGO, Illinois, May 2026 Tempus AI announced an expanded strategic collaboration with Bristol Myers Squibb aimed at improving the...
Tempus AI, Predicta Expand Genomics Test for Blood Cancer
Chicago, Illinois, U.S. | April 15, 2026 Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion...
Tempus, Daiichi Sankyo Advance AI in ADC Oncology Trials
CHICAGO, Illinois, March 25, 2026 Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate AI-driven biomarker...
Advertisements
Tempus Study Shows Genomic Profiling Expands Cancer Care
CHICAGO — March 11, 2026 Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence...
Whitehawk Therapeutics Identifies PTK7 as a Broadly Expressed ADC Target Across Solid Tumors
MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...
Advertisement
